Eton Pharmaceuticals (NASDAQ: ETON) Stock Analysis: H.C. Wainwright Boosts Price Target Amid Strong Performance

Font: Financial Modeling Prep  • May 15, 2026

• H.C. Wainwright reiterated a "Buy" rating and increased its price target for Eton Pharmaceuticals (NASDAQ: ETON).
• Eton Pharmaceuticals raised its 2026 revenue forecast and reported strong Q1 product sales growth.
• New product launches (DESMODA, HEMANGEOL) and pipeline advancements (ET-700, INCRELEX) signal future growth for the biotech firm.

Eton Pharmaceuticals (NASDAQ: ETON) is a company that develops and sells unique treatments for rare diseases. On May 15, 2026, analyst firm H.C. Wainwright confirmed its "Buy" rating for Eton Pharmaceuticals. The firm also increased its price target to $57 from $52, when the stock was trading at $29.76.

This positive analyst view follows the company's strong performance. Eton raised its full-year 2026 revenue forecast to exceed $120 million, up from a previous $110 million. This decision was supported by record first-quarter product sales of $24.30 million, which is a 73% increase over the same period in 2025.

The company's quarterly revenue of over $24 million beat analyst estimates by more than 8%. However, its earnings per share (EPS) of $0.05 missed the Zacks Consensus Estimate of $0.10, as highlighted by Zacks. EPS represents the company's profit allocated to each outstanding share of stock.

Confidence in future growth is also based on new products. Eton noted promising early progress from its recent launches of DESMODA and HEMANGEOL. These products were launched late in the first quarter, so their financial impact is expected to be seen in future results rather than the current report.

Further supporting its pipeline, Eton started a clinical study for ET-700 and received FDA clearance for a study on its existing product, INCRELEX. These activities show the company is actively working to expand its product offerings and improve current treatments, which can contribute to long-term value.